Opinion

attention-deficit drugs | editorial

Quota system breaks down

A NATIONWIDE shortage of medicines for attention-deficit hyperactivity disorder is causing undue stress to those with the ailment - or, more often, their parents. Individuals looking to refill prescriptions have to drive from pharmacy to pharmacy in search of hidden stockpiles of medicines like Ritalin, Adderall, and their generic counterparts.

As a result, patients are asking tough questions of the pharmaceutical industry and of government regulators. The Drug Enforcement Administration has shouldered much of the blame, since the agency limits how much of the amphetamine salts - the drugs’ active ingredients - can be distributed to manufacturers each year. That ire isn’t entirely justified: The DEA regulates amphetamines to prevent overflows from falling into the hands of their abusers - a large and growing population, especially among college students. The DEA also points out that the quota it set for pharmaceutical amphetamines last year was never depleted.

Your comment is subject to the rules of our Posting Policy

This comment may appear on your public profile. Public Profile FAQ

Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com